Faeth Therapeutics, Inc.

Total Valuation

Faeth Therapeutics, Inc. carries a market capitalization of 1.03B, placing it among publicly traded companies globally. Its enterprise value stands at 458.62M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Faeth Therapeutics, Inc. currently has 25.78M shares outstanding.

Valuation Ratios

Financial Position

Faeth Therapeutics, Inc. maintains a current ratio of 19.69, meaning it holds 19.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.34, indicating conservative leverage, while an interest coverage ratio of -22,077.44 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Stock Price Statistics

Faeth Therapeutics, Inc.'s stock has gained approximately 354.59705% over the past 52 weeks. The 50-day moving average sits at 29.55, while the 200-day moving average is 21.54.

Income Statement

EBITDA reached -198.70M, while operating income came in at -198.82M.

Balance Sheet

Faeth Therapeutics, Inc. holds 186.44M in cash and equivalents against 592,000.00 in total debt, resulting in a net debt position of -26.90M. Total book value stands at 172.96M, with working capital of 179.08M providing operational flexibility.

Cash Flow

Faeth Therapeutics, Inc. produced -33.86M in operating cash flow over the past twelve months. After subtracting -6,000.00 in capital expenditures, free cash flow totaled -33.86M - equivalent to -12.39 per share.

Dividends & Yields

Scores

Faeth Therapeutics, Inc. posts an Altman Z-Score of 17.85, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.